

**DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION**

DISTRICT OFFICE ADDRESS AND PHONE NUMBER 250 Marquette Ave, Ste 600 Minneapolis, MN 55401 (612) 334-4100 Fax: (612) 334-4134 Industry Information: www.fda.gov/oc/industry	DATE(S) OF INSPECTION 07/23, 24, 26, 30/2018
	FEI NUMBER 3012360920

NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT IS ISSUED
TO: Stephen G. Anderson, Owner


FIRM NAME W & C Apothecary dba The Apothecary	STREET ADDRESS 165 19th St S, Ste 102
CITY, STATE AND ZIP CODE Sartell, MN 56377-2567	TYPE OF ESTABLISHMENT INSPECTED Producer of non-sterile drugs

All products are made in these (b) (4) hoods, and any products made after these ceftazidime batches may be at risk of cephalosporin cross-contamination. For example:

- Batch 16201817@11, duloxetine/oil 15 mg/ml suspension, was produced on 05/24/2018 in (b) (4) hood #1.
- Batch 05201806@16, progesterone 275 mg capsule, was produced on 06/05/2018 in (b) (4) hood #2.

b. On 07/26/2018, I observed the production of batch 23201807@22, progesterone/testosterone 50/1 mg troche in (b) (4) hood #1. After production of this batch, pharmacy tech^{(b) (6)} applied (b) (4) (b) (4) solution to the hood, immediately wiped it up, therefore not leaving the (b) (4) for a (b) (4) minute contact time, and applied (b) (4) and allowed that to sit. Batch 26201807@11, testosterone ATR 100 mg/g gel, was the next batch produced after batch 23201807@22.

Add Continuation Page

SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE 	EMPLOYEE(S) NAME AND TITLE (<i>Print or Type</i>) Charles L. Zhou, Investigator	DATE ISSUED 07/30/2018
-----------------------------------	--	--	---------------------------